• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Root Jonathan D

    10/8/21 5:16:20 PM ET
    $LWAC
    Get the next $LWAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    ROOT JONATHAN D

    (Last) (First) (Middle)
    C/O EFFECTOR THERAPEUTICS, INC.
    11120 ROSELLE ST SUITE A,

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    eFFECTOR Therapeutics, Inc. [ EFTR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/06/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $11.36 10/06/2021 A 40,000 (1) 10/05/2031 Common Stock 40,000 $0.00 40,000 D
    Explanation of Responses:
    1. The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date.
    Remarks:
    /s/ Michael Byrnes, Attorney-in-Fact for Jonathan D. Root 10/08/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LWAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lightwave Founders Llc bought $6,062,500 worth of Class A ordinary shares (606,250 units at $10.00) (SEC Form 4)

    4 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:50:58 PM ET
    $LWAC

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Dickason Allen Charles

    3 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:54:59 PM ET
    $LWAC

    Large owner Lightwave Founders Llc bought $6,062,500 worth of Class A ordinary shares (606,250 units at $10.00) (SEC Form 4)

    4 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:50:58 PM ET
    $LWAC

    SEC Form 3 filed by new insider Lightwave Founders Llc

    3 - LightWave Acquisition Corp. (0002061379) (Issuer)

    6/24/25 9:27:54 PM ET
    $LWAC

    $LWAC
    SEC Filings

    View All

    SEC Form 10-Q filed by LightWave Acquisition Corp.

    10-Q - LightWave Acquisition Corp. (0002061379) (Filer)

    8/21/25 5:04:51 PM ET
    $LWAC

    SEC Form NT 10-Q filed by Locust Walk Acquisition Corp.

    NT 10-Q - LightWave Acquisition Corp. (0002061379) (Filer)

    8/14/25 5:26:46 PM ET
    $LWAC

    Amendment: SEC Form SCHEDULE 13G/A filed by Locust Walk Acquisition Corp.

    SCHEDULE 13G/A - LightWave Acquisition Corp. (0002061379) (Subject)

    8/14/25 10:06:25 AM ET
    $LWAC

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

    Dallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the closing of its initial public offering of 21,562,500 units at an offering price of $10.00 per unit. This includes the exercise in full by the underwriters of their over-allotment option to purchase up to an additional 2,812,500 units. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are listed on the Nasdaq Global Market ("N

    6/26/25 3:07:28 PM ET
    $LWAC

    LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

    Dallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 18,750,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the Company's initial business combination, will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are expected to trade on the Nasdaq Stock Market LLC ("Nasdaq") und

    6/24/25 6:44:57 PM ET
    $LWAC

    Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

    SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

    8/24/21 4:47:39 PM ET
    $LWAC

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/13/21 6:23:36 AM ET
    $LWAC

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/7/21 5:12:00 PM ET
    $LWAC

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/3/21 4:00:25 PM ET
    $LWAC